Sage Journals: Discover world-class research

Abstract

The aim of this study was to investigate protein expression of adenomatous polypois coli (APC) in primary and metastatic serous ovarian carcinoma. The expression of 3-catenin and E-cadherin was additionally analyzed. One hundred and thirteen priary (n=56) and metastatic (n=57) lesions were immunohistochemically stained for APC, E-cadherin, and f-catenin. Staining extent was scored. Possible differences in immunoreactivity in primary and metastatic sites and the association between the proteins analyzed were evaluated statistically. Cytoplasmic immunoreactivity for APC was found in 67/113 (59%) tumors, most often in the majority (>50%) of cells. E-cadherin was detected in 102/113 (90%) carcinomas, while P-catenin was exressed in 109/113 (97%) specimens. Nuclear expression of f-catenin was seen in 3/113 (3%) specimens, all negative for APC. APC and f-catenin were often coexressed, but this finding failed to reach statistical significance (p=0. 1 1). A significant association was seen between E-cadherin and f-catenin expression (p=0.001). APC expression was comparable in primary and metastatic tumors (p>0.05). In concluion, APC expression is absent in a considerable number of both primary and metastatic ovarian carcinomas, but this finding is only rarely coupled to nuclear acumulation of f-catenin. These findings support the role for f-catenin signaling via the Wingless/Wnt pathway in ovarian carcinoma. The mechanism behind the downegulated expression of APC in serous ovarian carcinoma and its significance has yet to be elucidated.

Keywords

adenomatous polyposis coli protein E-cadherin β-catenin serous ovarian carcinoma immunohistochemistry

Get full access to this article

View all access options for this article.

References

1. Hanahan D , Weinberg RA . The hallmarks of cancer. Cell 100:57-70, 2000

2. van Es JH , Giles RH , Clevers HC . The many faces of the tumor suppressor gene APC. Exp Cell Res 264:126-134, 2001

3. Pellman D . A CINtillating new job for the APC tumor suppressor. Science 291:2555-2556, 2001

4. Fearnhead NS , Britton MP , Bodmer WF . The ABC of APC. Hum Mol Genet 10:721-733, 2001

5. Beroud C , Soussi T . APC gene: Database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 24:121-124, 1996

6. Takeichi M . The Cadherins: Cell-cell adhesion moleules controlling animal morphogenesis. Developent 102:639-655, 1988

7. Shirayoshi Y , Hatta K , Hosoda M , Tsunasawa S , Sakiyama F , Takechi M . Cadherin cell adhesion molecules with distinct binding specificities share a common structure. EMBO J 5:2485-2488, 1986

8. Takeichi M . Cadherin cell adhesion receptors as a morhogenetic regulator. Science 51:1451-1455, 1991

9. Grunwald GB . The structural and functional analysis of cadherin calcium-dependent cell adhesion molcules. Curr Opin Cell Biol 5:797-805, 1993

10.

10. Behrens J . Cadherins and catenins: Role in signal transduction and tumor progression. Cancer Metast Rev 18:15-30,1999

11.

11. Shiozaki H , Oka H , Inoue M , Tamura S , Monden M . E-cadherin-mediated adhesion system in cancer cells. Cancer 77:1605-1613, 1996

12.

12. Polakis P . The oncogenic activation of P-catenin. Curr Opin Genet Dev 9:15-21, 1999

13.

13. Eastman Q , Grosschedl R . Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 11:233-240, 1999

14.

14. Bullions LC , Levine AJ . The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 10:81-87, 1999

15.

15. Morin PJ . I-catenin signaling and cancer. Bio Essays 21:1021-1030, 1999

16.

16. Parkin DM , Pisani P , Ferlay J . Global cancer statistics. CA Cancer J Clin 49:33-64, 1999

17.

17. Bjorge T , Engeland A , Hansen S , Trope CG . Prognosis of patients with ovarian cancer and borderline tuours diagnosed in Norway between 1954 and 1993. Int J Cancer 75:663-670, 1998

18.

18. Tavassoli M , Steingrimsdottir H , Pierce E , Jiang X , Alagoz M , Farzaneh F , Campbell IG . Loss of hetrozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumor suppressor gene locus at 5ql 3.1-21. Br J Cancer 74:115-119, 1996

19.

19. Weitzel JN , Patel J , Smith DM , Goodman A , Safaii H , Ball HG . Molecular genetic changes associated with ovarian cancer. Gynecol Oncol 55:245-252, 1994

20.

20. Abrahamson J , Moslehi R , Vesprini D , Karlan B , Fishan D , Smotkin D , Ben David Y , Biran H , Fields A , Brunet JS , Narod SA . No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. Cancer Res 58:2919-2922, 1998

21.

21. Gershoni-Baruch R , Patael Y , Dagan, Figer A , Kasinetz L , Kadouri E , Bruchim Bar Sade R , Friedan E . Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian caner: More questions than answers. Br J Cancer 83:153-155, 2000

22.

22. Furlong MT , Morin PJ . Rare activation of the TCF/Patenin pathway in ovarian cancer. Gynecol Oncol 77:97-104, 2000

23.

23. Palacios J , Gamallo C . Mutations in the P-catenin gene (CTNNB 1) in the endometrioid ovarian carciomas. Cancer Res 58:1344-1347, 1998

24.

24. Wright K , Wilson P , Mordland S , Campbell I , Walsh M , Hurst T , Ward B , Cummings M , Chevenix-Trench G . P-catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tuours. Int J Cancer 82:625-629, 1999

25.

25. Gamallo C , Palacios J , Moreno G , Calvo de Mora J , Suarez A , Armas A . f-catenin expression pattern in stage I and II ovarian carcinomas. Relationship with f-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155:527-536, 1999

26.

26. Sagae S , Kobayashi K , Nishioka Y , Sugimura M , Ishoka S , Nagata M , Terasawa K , Tokino T , Kudo R . Mutational analysis of, B-catenin gene in Japanese ovarian carcinomas: Frequent mutations in enometrioid carcinomas. Jpn J Cancer Res 90:510-515, 1999

27.

27. Young RH , Clement PB , Scully RE . Surface epithelialtromal tumors. In Sternberg SS , Antonioli DA , Carter D , Mills SE , Oberman HA (eds). Diagnostic surgical pathology, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, pp 2319-2382, 1999

28.

28. Webster MT , Rozycka M , Sara E , Davis E , Smalley M , Young N , Dale TC , Wooster R . Sequence variants of the Axin gene in breast, colon, and other cancers: An analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 28:443-453, 2000

29.

29. Davidson B , Berner A , Nesland JM , Risberg B , Berner HS , Trope CG , Kristensen GB , Bryne M , Florenes V-A . E-cadherin and a-,, Bnd y-catenin protein exression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 192:460-469, 2000

30.

30. Davidson B , Gotlieb WH , Ben-Baruch G , Nesland JM , Bryne M , Goldberg L Kopolovic J , Bemer A . E-caderin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 79:362-371, 2000

31.

31. Risinger JI , Berchuck A , Kohler MF , Boyd J . Mutaions of the E-cadherin gene in human gynecologic cancers. Nature Genet 7:98-102, 1994

Adenomatous Polyposis Coli (APC) Protein Expression in Primary and Metastatic Serous Ovarian Carcinoma

Abstract

Keywords

Get full access to this article

References